DNA methylation regulates CHRNA7 transcription and can be modulated by valproate

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

DNA methylation regulates CHRNA7 transcription and can be modulated by valproate. / Dyrvig, Mads; Mikkelsen, Jens D.; Lichota, Jacek.

In: Neuroscience Letters, Vol. 704, 06.2019, p. 145-152.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Dyrvig, M, Mikkelsen, JD & Lichota, J 2019, 'DNA methylation regulates CHRNA7 transcription and can be modulated by valproate', Neuroscience Letters, vol. 704, pp. 145-152. https://doi.org/10.1016/j.neulet.2019.04.015

APA

Dyrvig, M., Mikkelsen, J. D., & Lichota, J. (2019). DNA methylation regulates CHRNA7 transcription and can be modulated by valproate. Neuroscience Letters, 704, 145-152. https://doi.org/10.1016/j.neulet.2019.04.015

Vancouver

Dyrvig M, Mikkelsen JD, Lichota J. DNA methylation regulates CHRNA7 transcription and can be modulated by valproate. Neuroscience Letters. 2019 Jun;704:145-152. https://doi.org/10.1016/j.neulet.2019.04.015

Author

Dyrvig, Mads ; Mikkelsen, Jens D. ; Lichota, Jacek. / DNA methylation regulates CHRNA7 transcription and can be modulated by valproate. In: Neuroscience Letters. 2019 ; Vol. 704. pp. 145-152.

Bibtex

@article{8037e6219ba343d093b5e5bf6164f700,
title = "DNA methylation regulates CHRNA7 transcription and can be modulated by valproate",
abstract = "The CHRNA7 gene encoding the α7 nicotinic acetylcholine receptor (nAChR) has repeatedly been linked with schizophrenia and the P50 sensory gating deficit. The α7 nAChR is considered a promising drug target for treatment of cognitive dysfunction in schizophrenia and improves memory and executive functions in patients and healthy individuals. However, clinical trials with pro-cognitive drugs are challenged by large inter-individual response variations and these have been linked to genotypic variations reducing CHRNA7 expression and α7 nAChR function. Genetic variants as well as environmental conditions may cause epigenetic dysregulation and it has previously been found that DNA methylation of a region surrounding the transcription start site of CHRNA7 is important for tissue specific regulation and gene silencing. In the present study we identify two additional regions involved in epigenetic regulation of the CHRNA7 promoter. In human temporal cortex we find large variations in expression of CHRNA7 and establish evidence for a significant correlation with DNA methylation levels of one region. We then establish evidence that genotypic variations can influence methylation levels of the CHRNA7 promoter. Epigenetic dysregulation can be reversed by pharmacological intervention and in HeLa cells. Valproate, a commonly used mood stabiliser, caused demethylation and increased CHRNA7 expression in HeLA cells. Similar demethylation effect and increased CHRNA7 expression was obtained in SH-SY5Y cells stimulated concomitantly with valproate and nicotine. In summary, both genetic and epigenetic information could be useful to predict treatment outcomes in patients and epigenetic modulation may serve as a mechanism for potentiating the effects of α7 nAChR agonists.",
keywords = "CHRNA7, DNA methylation, Gene expression, Promoter SNP, Schizophrenia, Valproate",
author = "Mads Dyrvig and Mikkelsen, {Jens D.} and Jacek Lichota",
year = "2019",
month = jun,
doi = "10.1016/j.neulet.2019.04.015",
language = "English",
volume = "704",
pages = "145--152",
journal = "Neuroscience letters. Supplement",
issn = "0167-6253",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - DNA methylation regulates CHRNA7 transcription and can be modulated by valproate

AU - Dyrvig, Mads

AU - Mikkelsen, Jens D.

AU - Lichota, Jacek

PY - 2019/6

Y1 - 2019/6

N2 - The CHRNA7 gene encoding the α7 nicotinic acetylcholine receptor (nAChR) has repeatedly been linked with schizophrenia and the P50 sensory gating deficit. The α7 nAChR is considered a promising drug target for treatment of cognitive dysfunction in schizophrenia and improves memory and executive functions in patients and healthy individuals. However, clinical trials with pro-cognitive drugs are challenged by large inter-individual response variations and these have been linked to genotypic variations reducing CHRNA7 expression and α7 nAChR function. Genetic variants as well as environmental conditions may cause epigenetic dysregulation and it has previously been found that DNA methylation of a region surrounding the transcription start site of CHRNA7 is important for tissue specific regulation and gene silencing. In the present study we identify two additional regions involved in epigenetic regulation of the CHRNA7 promoter. In human temporal cortex we find large variations in expression of CHRNA7 and establish evidence for a significant correlation with DNA methylation levels of one region. We then establish evidence that genotypic variations can influence methylation levels of the CHRNA7 promoter. Epigenetic dysregulation can be reversed by pharmacological intervention and in HeLa cells. Valproate, a commonly used mood stabiliser, caused demethylation and increased CHRNA7 expression in HeLA cells. Similar demethylation effect and increased CHRNA7 expression was obtained in SH-SY5Y cells stimulated concomitantly with valproate and nicotine. In summary, both genetic and epigenetic information could be useful to predict treatment outcomes in patients and epigenetic modulation may serve as a mechanism for potentiating the effects of α7 nAChR agonists.

AB - The CHRNA7 gene encoding the α7 nicotinic acetylcholine receptor (nAChR) has repeatedly been linked with schizophrenia and the P50 sensory gating deficit. The α7 nAChR is considered a promising drug target for treatment of cognitive dysfunction in schizophrenia and improves memory and executive functions in patients and healthy individuals. However, clinical trials with pro-cognitive drugs are challenged by large inter-individual response variations and these have been linked to genotypic variations reducing CHRNA7 expression and α7 nAChR function. Genetic variants as well as environmental conditions may cause epigenetic dysregulation and it has previously been found that DNA methylation of a region surrounding the transcription start site of CHRNA7 is important for tissue specific regulation and gene silencing. In the present study we identify two additional regions involved in epigenetic regulation of the CHRNA7 promoter. In human temporal cortex we find large variations in expression of CHRNA7 and establish evidence for a significant correlation with DNA methylation levels of one region. We then establish evidence that genotypic variations can influence methylation levels of the CHRNA7 promoter. Epigenetic dysregulation can be reversed by pharmacological intervention and in HeLa cells. Valproate, a commonly used mood stabiliser, caused demethylation and increased CHRNA7 expression in HeLA cells. Similar demethylation effect and increased CHRNA7 expression was obtained in SH-SY5Y cells stimulated concomitantly with valproate and nicotine. In summary, both genetic and epigenetic information could be useful to predict treatment outcomes in patients and epigenetic modulation may serve as a mechanism for potentiating the effects of α7 nAChR agonists.

KW - CHRNA7

KW - DNA methylation

KW - Gene expression

KW - Promoter SNP

KW - Schizophrenia

KW - Valproate

U2 - 10.1016/j.neulet.2019.04.015

DO - 10.1016/j.neulet.2019.04.015

M3 - Journal article

C2 - 30974230

AN - SCOPUS:85064151647

VL - 704

SP - 145

EP - 152

JO - Neuroscience letters. Supplement

JF - Neuroscience letters. Supplement

SN - 0167-6253

ER -

ID: 241991745